N
NexCure
Community outpatient centers for advanced cancer therapies.
About NexCure
NexCure, Inc. is a healthcare company that operates outpatient oncology treatment centers to deliver advanced therapies like CAR-T and T-cell engagers. The company launched in March 2026 with a $19 million Series A financing round led by RA Capital Management, with Cencora Ventures and Oncology Ventures participating. NexCure was founded in 2024 by Raven, RA Capital's healthcare incubator, to address the significant access and capacity limitations for complex cancer treatments. Currently, only about 3% of U.S. hospitals administer CAR-T therapy, leaving a large portion of eligible patients without access.
Read full description
The company was co-founded by Dr. Paul Rothman and Dr. Sophie Papa. Dr. Rothman, who serves as Board Chair, is a former Dean of Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine. Dr. Papa, the Chief Medical Officer, is an internationally recognized expert in cellular therapy. The leadership team also includes CEO Jennifer Smith, who has over 20 years of healthcare operations experience, and Co-founder & Chief Business Officer Anish More.
NexCure's business model involves partnering with health systems to build and operate a network of community-based, outpatient treatment centers. This strategy aims to bring life-saving therapies closer to patients' homes, removing geographic, financial, and logistical barriers to care. The model serves patients, referring oncologists, health systems, payers, and biopharmaceutical manufacturers. The company's proprietary platform integrates AI-powered patient selection, remote monitoring, and standardized clinical protocols to ensure safe and personalized treatment. By standardizing protocols and automating care coordination, NexCure aims to reduce operational variability and enable the delivery of advanced therapies outside of a few large academic medical centers.
At a glance
- Status
- Operational
- Founded
- 2025
- Headquarters
- Boston, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 61.9/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Oncology, Chronic Disease, Core AI, Immune System
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning NexCure.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2026 | $19M | $76M | Cencora Ventures · Oncology Ventures · RA Capital Management | ↗ |
Growth signals
Latest recorded traffic for NexCure is 1.2K monthly website visits, down 40% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
RA Capital Management- CVCencora Ventures
Oncology Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NexCure on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NexCure’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.